HR 2148 117th Congress House Health Administrative remedies Asia Business records Canada Civil actions and liability Competition and antitrust Department of Health and Human Services Drug safety, medical device, and laboratory regulation Europe France Germany Government information and archives Government studies and investigations Health care costs and insurance Health information and medical records Inflation and prices Intellectual property Japan Licensing and registrations

Prescription Drug Price Relief Act of 2021

Introduced: March 23, 2021 Introduced by: Khanna, Ro Democratic · California See on congress.gov

Everywhere this bill has been 4 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Oct 19, 2021

Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Mar 24, 2021

Referred to the Subcommittee on Health.

Mar 23, 2021

Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Mar 23, 2021

Introduced in House

Plain-English summary Congressional Research Service

Prescription Drug Price Relief Act of 2021

This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs.

Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.

Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population.

The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

What's happening now October 19, 2021

Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Committees of jurisdiction 4